Matches in Nanopublications for { ?s ?p "[To evaluate the immunological and clinical response as well as the safety of the optimized peptide telomerase reverse transcriptase p572Y (TERT572Y) presented by HLA-A*0201 in patients with advanced non-small-cell lung cancer (NSCLC).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- NP325028.RAeug2fviqNBhvGZiyGrzMJJEkYNOdeTAm6lRsE6gcASY130_assertion description "[To evaluate the immunological and clinical response as well as the safety of the optimized peptide telomerase reverse transcriptase p572Y (TERT572Y) presented by HLA-A*0201 in patients with advanced non-small-cell lung cancer (NSCLC).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP325028.RAeug2fviqNBhvGZiyGrzMJJEkYNOdeTAm6lRsE6gcASY130_provenance.
- NP472336.RAgk7CJ57rwUUnfHaEtB8tH1nOVzDog5Clr9-ftDPn96g130_assertion description "[To evaluate the immunological and clinical response as well as the safety of the optimized peptide telomerase reverse transcriptase p572Y (TERT572Y) presented by HLA-A*0201 in patients with advanced non-small-cell lung cancer (NSCLC).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP472336.RAgk7CJ57rwUUnfHaEtB8tH1nOVzDog5Clr9-ftDPn96g130_provenance.
- NP450661.RA4ElU7c6O2H2B10YJJ5XF3cgDkFOY5mNrwn7oa3IifC8130_assertion description "[To evaluate the immunological and clinical response as well as the safety of the optimized peptide telomerase reverse transcriptase p572Y (TERT572Y) presented by HLA-A*0201 in patients with advanced non-small-cell lung cancer (NSCLC).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP450661.RA4ElU7c6O2H2B10YJJ5XF3cgDkFOY5mNrwn7oa3IifC8130_provenance.
- assertion description "[To evaluate the immunological and clinical response as well as the safety of the optimized peptide telomerase reverse transcriptase p572Y (TERT572Y) presented by HLA-A*0201 in patients with advanced non-small-cell lung cancer (NSCLC).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP617805.RA_l1J9xPjEjpTaL_Ba4PSl2jN7fVP4RFOw6L_SU8CzJM130_assertion description "[To evaluate the immunological and clinical response as well as the safety of the optimized peptide telomerase reverse transcriptase p572Y (TERT572Y) presented by HLA-A*0201 in patients with advanced non-small-cell lung cancer (NSCLC).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP617805.RA_l1J9xPjEjpTaL_Ba4PSl2jN7fVP4RFOw6L_SU8CzJM130_provenance.